Inclusion Criteria:

• * Have a body mass index within the range of 18.0 to 32 kilograms per square meter (kg/m²)
• * Males who agree to follow contraceptive requirements and women of not childbearing potential
• * Have body weight greater than or equal to (\>=) 50 Kilograms at screening.
• * Must have a negative Interferon-Gamma Release Assays (IGRA) testing at screening
• * Must have been stopped all the prescribed medication at least 14 days prior to admission to the clinical site
• * Ability and willingness to abstain from alcohol, caffeine, and methylxanthine-containing beverages or food 2 days prior to admission to the clinical site
• * Abstain from any strenuous physical exercise from 4 days prior to admission and during confinement at the clinical site

Exclusion Criteria:

• * Have a history of relevant drug and/or food allergies, or sensitivity to medications used in the current study
• * Females participants who are currently breastfeeding
• * Have History of alcohol abuse or drug addiction
• * Unable to abstain from tobacco products within the 2 days prior to admission and during confinement at the clinical site
• * Have Positive screen for hepatitis B surface antigen, hepatitis C virus (HCV) antibodies, or human immunodeficiency virus (HIV) 1 and 2 antibodies
• * Consumption of any nutrients known to modulate CYP450 enzymes activity
• * Are immunocompromised
• * Have received live vaccine(s) (including attenuated live vaccines) or Bacillus Calmette-Guérin within 28 days of screening or intend to receive them during the study
• * Have had any malignancy within the past 5 years